SCHEMBL27613656

SCHEMBL27613656

CN(C)c1cccc2c(S(=O)(=O)c3ccc(N)c4ccccc34)cccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.64
CHEK1 O14757 1/20 0.64
NEK2 P51955 1/20 0.64
LIMK1 P53667 1/20 0.64
DYRK1A Q13627 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64
F2 P00734 3/20 0.55
PRSS1 P07477 3/20 0.55
PRSS2 P07478 3/20 0.55
PRSS3 P35030 3/20 0.55
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTT P42858 1/20 0.54
HIF1A Q16665 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KMT2A Q03164 1/20 0.51
ATM Q13315 1/20 0.51
EDNRA P25101 5/20 0.49
NSD2 O96028 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10344364 0.88 CA2 (0.60) CA2CHEK1NEK2LIMK1DYRK1A
SCHEMBL18669851 0.84 CA2 (0.63) CA2F2PRSS1PRSS2PRSS3
SCHEMBL11127453 0.81 CA2 (0.64) CA2F2PRSS1PRSS2PRSS3
SCHEMBL28977923 0.80 CA2 (0.62) CA2CHEK1NEK2LIMK1DYRK1A
SCHEMBL29921971 0.79 CHEK1 (1.00) CA2CHEK1NEK2LIMK1DYRK1A
SCHEMBL4078292 0.79 CHEK1 (1.00) CA2CHEK1NEK2LIMK1DYRK1A
SCHEMBL108421 0.78 CA2 (1.00) CA2F2PRSS1PRSS2PRSS3
SCHEMBL8522841 0.78 CA2 (0.55) CA2F2PRSS1PRSS2PRSS3
SCHEMBL29550086 0.78 CA2 (0.55) CA2F2PRSS1PRSS2PRSS3
SCHEMBL17294738 0.78 CA2 (0.55) CA2F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100356923-C Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders NOVARTIS AG (CH) 2007-12-26 CN disclosed
CN-101062932-A Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof NOVARTIS AG (CH) 2007-10-31 CN disclosed
CN-1933819-A Oral matrix formulations comprising licarbazepine NOVARTIS AG (CH) 2007-03-21 CN disclosed
CN-1933817-A Disintegrating tablets comprising licarbazepine NOVARTIS AG (CH) 2007-03-21 CN disclosed
CN-1767834-A Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders NOVARTIS AG (CH) 2006-05-03 CN disclosed
CN-1750826-A Use of R-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain NOVARTIS AG (CH) 2006-03-22 CN disclosed
CN-1747735-A Use of S-10-hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders NOVARTIS AG (CH) 2006-03-15 CN disclosed
CN-1703404-A Enantioselective process for preparing two enantiomers of 10, 11-dihydro-10-hydroxy-5H-dibenzo (b, f) azepine * -5-carboxamide and novel crystalline forms thereof NOVARTIS AG (CH) 2005-11-30 CN disclosed
CN-1674909-A Use of carboxamides for the treatment of tinnitus NOVARTIS AG (CH) 2005-09-28 CN disclosed